Xtandi – Replacing competitor from Zytiga to Casodex (Bicalutamide) for a bigger pie in Prostate cancer & Finding its niche in crowded BC market
Xtandi + Zytiga vs. ARN-509 + Zytiga - Who will win the race?
Rising star Anti Androgens – Third generation Antiandrogens- What left for AR-V7 mutants after TOK-001 failure?
Late Stage Prostate Cancer Pipeline drugs – AKT inhibitors or PARP inhibitors or a new MoA combination with Antiandrogen or IO combo - Competing to Xtandi/Zytiga or targeting Xtandi/Zytiga Resistance Population?
Increase in prevalence of Prostate cancer and availability of new treatment options (Zytiga, Xtandi, Cabazitaxel and Xofigo) in last few years has extended role of newer oral Antiandrogens to treat metastatic CRPC patient populations where the unmet need was high. This has expanded WW market size of Prostate cancer drugs to $7b in 2016 from $2.5b in 2011. Now nmCRPC, HSPC and Xtandi/Zytiga resistance population are the markets where in new pipeline drugs are under development.
Reported PhII clinical data of Xtandi, ARN-509 and ODM-201 in nmCRPC when indirectly compared demonstrate the bar is high for ARN-509 to compete against Xtandi in nmCRPC market and while ODM-201 is few years behind in clinical development. While in mHSPC reported clinical results of STAMPEDE study opens door for docetaxel combination approach as standard of care in first line setting.
Around 8 plus drugs are in PhIII development for Prostate cancer treatment and 26 plus drugs are in PhII development (21 small molecules) - success of a few (ARN-509, ODM-201, AZD 5363, GX301) in coming years will expand nmCRPC ($3.5be), mHSPC market ($1be) and Xtandi/Zytiga resistant population ($1be) market by 2023. Longer duration of therapy and high prevalence makes earlier setting market more attractive and bigger for newer options than the late stage if they succeed.
For drugs targeting through androgen pathway - Now trials and clinical development is underway for second and third generation androgen receptor inhibitors (ARN-509, ODM-201, ODM-204, EPI-506, VT-464, TAS-3681 and DR103). While androgen synthesis inhibitors still needs a proof of concept in clinic due to failure of TAK-700 & TOK-001. Expected data from VT-464 (Apr 2017) & ASN-001 will be important to watch to taste the success for this class. Androgen receptor degrader is another MoA in development from a decade and success of in clinic compound GTX-758 (Data expected anytime from now as study completed in March 2016- less likely to succeed) will decide the proof of concept.
Other than pipeline drugs targeting androgen pathway, NCE targeting AKT pathway (AZD5363, Ipatasertib) appears to be more promising to succeed in late stage, while drugs acting through PARP inhibition (Olaparib, Niraparib) still needs a taste of success. Other interesting pipeline asset is LHRH agonist LMIS 50 mg, which is designed to overcome the drawbacks of the commercial depot products containing GnRH agonists by using a proprietary delivery system.
Also 6 therapeutic vaccines are in clinical development to treat prostate cancer. Recently launched PD-L1 IO therapy has increased hope of treating cancer in much safer way. Current ongoing studies of late stage IO mab are in Ph I/II clinical development and would be able to answer of PTEN hypothesis for role of PD-1, PD-L1 inhibitor to treat prostate cancer in coming years.
Resistant development is another challenge with long term use of Xtandi/Zytiga and needs to be addressed by pipeline second/third generation Antiandrogens/ combination approach with IO/PARP/AKT inhibitors to treat mCRPC. Increase in pricing pressure in developed market again put inference on Combination approach unless the advantage is significant and improve the Q0L in earlier setting. Due to that, drugs targeting adjuvant setting has high bar to deliver (Atezolizumab, GX301, Mipsagargin and Olaparib) in the clinical development to add significant value.
This report details current unmet need, changing regulatory requirement, reimbursement challenges & market dynamics of Prostate Cancer drugs. Report mention pipeline Antiandrogens, late stage prostate cancer pipeline drugs/new Mechanism of action & major companies developing Prostate cancer drugs. It also provides insight on clinical development strategy of combination pipeline/marketed drugs & therapeutic competitive landscape to find treatment paradigm fit & market potential of new drugs for treatment of Prostate Cancer
Our reports have been used by over 10K customers, including:
The North America Radiotherapy Market would witness market growth of 5.6% CAGR during the forecast period (2022-2028). Radiation therapy could be the only option for some patients. However, radiation therapy is typically combined with other cancer treatments such as chemotherapy, surgery, and immunotherapy. To increase the likelihood...
The Asia Pacific Interventional Oncology Market would witness market growth of 6.7% CAGR during the forecast period (2022-2028). One of the newest and most promising applications of IO is the precise delivery of innovative therapeutic medicines into tumours through catheter or direct intratumoral injection. Guided imaging had also been...
Summary Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company that focuses on the development of tests for various types of cancers.The company’s flagship product, Cologuard test is a US FDA-approved non-invasive stool-based deoxyribonucleic acid (DNA) screening product indicated for the early detection...
Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 188.8.131.52) - Drugs in Development, 2021 Summary Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 184.108.40.206) pipeline Target constitutes close to 9 molecules. Out of which approximately...
Summary Precision Biologics Inc (PBI), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company.The company offers cancer vaccines, antigens and antibodies, pipelines, diagnostics, therapeutics, clinical trials, tumor-specific antigens, companion diagnostic programs, and diagnostic biomarker for pancreatic...
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 220.127.116.11) - Drugs in Development, 2021 Summary Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 18.104.22.168) - Proto-oncogene serine/threonine-protein kinase Pim-1 is an enzyme encoded by the PIM1 gene. It promotes...
Tyrosine Protein Kinase CSK - Pipeline Review, H1 2020 Summary According to the recently published report ’Tyrosine Protein Kinase CSK – Pipeline Review, H1 2020’; Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 22.214.171.124) pipeline Target constitutes close...
404 pages •
By IQ4I Research & Consultancy Pvt. Ltd
• Mar 2020
Interventional Oncology (IO) is a rapidly growing field in cancer care that uses minimally invasive procedures performed under image guidance to diagnose and treat patients with liver, kidney, lung, and other cancers. Rather than removing tumors through open surgical procedures, these image-guided procedures can be...
Tyrosine Protein Kinase CSK - Pipeline Review, H2 2019 Summary Tyrosine Protein Kinase CSK (C Src Kinase or Protein Tyrosine Kinase CYL or CSK or EC 126.96.36.199) - Tyrosine-protein kinase CSK also known as C-terminal Src kinase is an enzyme that, in humans, is encoded by the CSK gene. It plays an important...
Summary Oxford Gene Technology Ltd (OGT) is a biotechnology company that develops biomarkers. The company offers automation products, chromosome-specific arrays, custom arrays, fish probes, gene-focused arrays, genome-wide arrays, NGS products, reagents and consumables and software. It offers services such as targeted sequencing...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.